Opendata, web and dolomites

AFactory SIGNED

THE FUTURE OF FOOD: Disrupting protein production with microalgae

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AFactory project word cloud

Explore the words cloud of the AFactory project. It provides you a very rough idea of what is the project "AFactory" about.

ramp    2018    unprecedented    start    aquae    output    effectiveness    ingredients    fto    critical    afa    jeopardizing    massive    share    expectations    unpredictability    kyanos    relies    partnership    dynamics    space    dietary    safety    boosts    2023    schedule    plant    award    grow    actions    full    channels    survey    prescription    unlimited    drawing    capacity    job    demand    indirect    industrial    exports    infrastructure    presumably    creations    pilot    people    95    onwards    eliminates    caters    line    protein    gaining    sources    compact    inducing    summit    takes    environment    10    companies    running    downside    efficient    health    won    commercialization    initial    smarter    110    supplements    sold    times    flos    aphanizomenon    healthy    cyclotrophy    2050    devised    first    billion    secure    functional    global    altran    market    margin    initiate    ip    factory    supply    microorganisms    food    thanks    powder    lab    france    smei1    yields    contaminants    group    disruptive    french    microalgae    environmentally    environmental    industry   

Project "AFactory" data sheet

The following table provides information about the project.

Coordinator
KYANOS BIOTECHNOLOGIES 

Organization address
address: 23 AVENUE DE LOMBEZ APT 21 BATIMENT
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.kyanos.bio
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KYANOS BIOTECHNOLOGIES FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

'By 2050, providing food for 10 billion people will become critical. Current protein sources cannot scale up without jeopardizing the environment. French start-up Kyanos has developed a disruptive plant-based protein production technology with no environmental downside. Its unlimited supply potential is in line with the food industry requirements. With unprecedented yields, cost effectiveness and health safety conditions, this industrial process, called 'Cyclotrophy' caters for the growing market expectations for healthy, environmentally-friendly products. Cyclotrophy won the Most Novel Protein Process & IT award at the Protein Summit 2018. It boosts the production of microorganisms such as microalgae and eliminates the unpredictability and the contaminants that affect traditional microalgae production. The process relies on smarter, more compact and more efficient production infrastructure and takes 20 times less space for a similar output. A fully functional lab-scale pilot is already running using AFA microalgae (Aphanizomenon flos-aquae). Thanks to a partnership with Altran Group, Kyanos is now about to ramp-up to the industrial scale. The production capacity of the first factory is devised to quickly grow to reach 100 tonnes of AFA microalgae per year by 2023. Kyanos will first target the high-margin dietary supplements market before addressing the massive food-ingredients demand. Drawing on existing distribution channels and health prescription dynamics, the initial product, AFA microalgae powder, will be sold to global health supplements companies. Kyanos will initiate EU distribution from year 2 onwards. In 2023, exports throughout Europe will represent 95% of the production, presumably gaining a 10% market share and inducing up to 110 indirect job creations in France and Europe The objectives of the SMEi1 are: to secure full-scale design for the Cyclotrophy process scale-up; IP, FTO analysis and global market survey to schedule commercialization actions.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AFACTORY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AFACTORY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More